OptimizeRx (OPRX) Expected to Post Earnings on Thursday

OptimizeRx (NASDAQ:OPRX) is projected to post its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to post earnings of $0.18 per share and revenue of $21.19 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 4:30 PM ET.

OptimizeRx (NASDAQ:OPRX) last announced its quarterly earnings data on Wednesday, August 12th. The company reported $0.16 EPS for the quarter, beating the consensus estimate of $0.11 by $0.05. The firm had revenue of $20.50 million for the quarter, compared to analyst estimates of $20.20 million. OptimizeRx had a return on equity of 9.44% and a net margin of 4.66%. On average, analysts expect OptimizeRx to post $0.49 EPS for the current fiscal year and $0.66 EPS for the next fiscal year.

OptimizeRx Stock Performance

Shares of NASDAQ OPRX opened at $9.30 on Thursday. The stock has a market cap of $175.21 million, a price-to-earnings ratio of 40.44 and a beta of 1.26. The company has a current ratio of 5.58, a quick ratio of 5.58 and a debt-to-equity ratio of 0.14. OptimizeRx has a 1-year low of $4.54 and a 1-year high of $21.56. The stock’s 50-day moving average is $8.15 and its 200 day moving average is $7.40.

Analyst Ratings Changes

OPRX has been the subject of several research reports. B. Riley Financial upped their target price on OptimizeRx from $10.00 to $11.00 and gave the stock a “buy” rating in a research note on Tuesday, September 29th. UBS Group set a $11.00 price target on shares of OptimizeRx in a research report on Friday, August 14th. Citizens Jmp lifted their price target on shares of OptimizeRx from $9.00 to $11.00 and gave the stock a “market outperform” rating in a research note on Friday, August 14th. Stifel Nicolaus set a $12.00 price objective on shares of OptimizeRx in a report on Thursday, August 13th. Finally, Wall Street Zen lowered shares of OptimizeRx from a “strong-buy” rating to a “buy” rating in a report on Monday, July 20th. Six investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, OptimizeRx presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.57.

OptimizeRx Company Profile

OptimizeRx Corporation (NASDAQ: OPRX) is a digital health and life sciences technology company that helps pharmaceutical and biotechnology companies connect with healthcare professionals and patients. Its platform supports prescription-related communications, treatment access, affordability, adherence and patient engagement throughout the medication journey.

The company provides solutions that can be integrated into electronic health records and other healthcare workflows. Its offerings include point-of-care messaging for healthcare professionals, patient support and savings programs, medication access tools, and data and analytics services designed to help life sciences companies communicate with relevant audiences and understand engagement.

OptimizeRx was founded in 2006 and has primarily served the U.S.